(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 May 2020 (22.05.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/102499 A2

(51) International Patent Classification:
A61K 9/127 (2006.01) *C12N 15/88* (2006.01)

(21) International Application Number:
PCT/US2019/061424

(22) International Filing Date:
14 November 2019 (14.11.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/767,358 14 November 2018 (14.11.2018) US
62/900,064 13 September 2019 (13.09.2019) US

(71) Applicant: **FLAGSHIP PIONEERING INNOVATIONS V, INC.** [US/US]; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US).

(72) Inventors: **VON MALTZAHN, Geoffrey, A.**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **RUBENS, Jacob, Rosenblum**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **SHAH, Jagesh, Vijaykumar**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **RUZO MATIAS, Albert**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **PUCCI, Ferdinando**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **MILWID, John, Miles**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **MEE, Michael, Travis**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **GORDON, Neal, Francis**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US).

(74) Agent: **KOYFMAN, Hannah, R.** et al.; Lando & Anastasi, LLP, 60 State Street, 23rd Floor, Boston, MA 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2020/102499 A2

(54) Title: FUSOSOME COMPOSITIONS FOR CNS DELIVERY

(57) Abstract: The present disclosure provides, at least in part, methods and compositions for in vivo fusosome delivery. In some embodiments, the fusosome comprises a combination of elements that promote specificity for target cells, e.g., one or more of a fusogen, a positive target cell-specific regulatory element, and a non-target cell-specific regulatory element. In some embodiments, the fusosome comprises one or more modifications that decrease an immune response against the fusosome.